CRP and rheumatoid arthritis: p38-MAPK inhibitors have been associated with tachyphylaxis in patients with rheumatoid arthritis and other inflammatory diseases, in which early reduction in inflammatory markers such as C-reactive protein (CRP) did not persist despite continued treatment [5, 9, 11].